Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Sarepta Therapeutics (SRPT) reported $413.46 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 63.1%. EPS of $0.73 for the same period compares to -$0.97 a year ago.

The reported revenue represents a surprise of +10.91% over the Zacks Consensus Estimate of $372.8 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +763.64%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Product, net: $359.48 million compared to the $360.31 million average estimate based on eight analysts.
  • Revenues- Product, net- ELEVIDYS: $133.94 million versus $131.40 million estimated by seven analysts on average.
  • Revenues- Product, net- EXONDYS 51: $120.17 million versus the six-analyst average estimate of $127.57 million.
  • Revenues- Product, net- AMONDYS 45: $71.92 million versus $68.04 million estimated by six analysts on average.
  • Revenues- Product, net- VYONDYS 53: $33.45 million versus the six-analyst average estimate of $32.40 million.
  • Revenues- Collaboration: $53.98 million compared to the $20.87 million average estimate based on four analysts.
View all Key Company Metrics for Sarepta Therapeutics here>>>

Shares of Sarepta Therapeutics have returned -0.3% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.